research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
De nouvelles thérapies promettent de mieux traiter la perte de cheveux due à l'alopécie androgénétique.
Search
for
Sort by
Research
330-360 / 1000+ results 
research A Concise Review on Novel Drugs Applied in Treatment of Alopecia
New therapies like JAK inhibitors, PRP, and stem cell treatments show promise for better alopecia management.
research Modern Management Approaches for Alopecia Areata
Janus kinase inhibitors effectively treat alopecia areata but may cause relapses and have long-term safety concerns.
research Update: baricitinib for alopecia areata
Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
research Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy
Deucravacitinib helped a man regrow hair significantly.
research Ponatinib-induced pityriasis rubra pilaris-like adnexal dysmaturation: A case report
Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
research Epidermal growth factor receptor mutant T790M-L858R-V948R inhibitor from Calophyllum inophyllum L. leaf as potential non-small cell lung cancer drugs
A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.
research Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series
Upadacitinib may effectively treat alopecia areata without side effects.
research Tribuloside acts on the PDE/cAMP/PKA pathway to enhance melanogenesis, melanocyte dendricity and melanosome transport
Tribuloside can increase skin pigmentation by enhancing melanin production and distribution.
research Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
Tofacitinib helped a woman with total-body hair loss grow her hair back.
research Screening for latent infectious disease in patients with alopecia areata before initiating JAK inhibitors therapy: a single-center real-world retrospective study
Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
research Advances in the mechanism and new therapies of alopecia areata
New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
research An Updated in the Management of Alopecia Areata
New treatments for alopecia areata show promise, but more research is needed to confirm their effectiveness.
research Treatment Patterns and Unmet Needs in the Management of Alopecia Areata: Results of a Physician’s Survey in the Middle East
Doctors in the Middle East need better treatments and more knowledge about new therapies for hair loss condition Alopecia Areata.
research BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience
Baricitinib was effective and safe for severe hair loss treatment over 6 months.
research Overview of alopecia areata for managed care and payer stakeholders in the United States
Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.
research Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
research New Treatment Strategies in Management of Alopecia Areata: Review Article
New treatments for sudden hair loss include oral medications and a special laser, both showing promise in hair regrowth.
research Ann Robinson’s research reviews —12 May 2022
Self-monitoring blood pressure in pregnant women didn't improve outcomes, diabetes drugs may increase gallbladder disease risk, a new drug helps severe hair loss, a plant-based COVID-19 vaccine is 69.5% effective, and new anticoagulants are safer for diabetics with heart rhythm issues than warfarin.
research Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
research Skin Cancer: Mechanisms and Human Relevance
Skin cancer involves complex mechanisms, risk factors, and can be potentially prevented with strategies like dietary changes and certain compounds.
research Alopecia areata
Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
research Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
research Leptin and the skin: a new frontier
Leptin may improve skin regeneration and hair growth, and help reverse skin aging.
research Influence of prostaglandin F2α and its analogues on hair regrowth and follicular melanogenesis in a murine model
Prostaglandin F2alpha and related compounds can increase hair growth and darken hair in mice.
research Phospholipase C 1 is required for skin stem cell lineage commitment
Phospholipase Cδ1 is crucial for normal skin and hair development.
research Topical Ruxolitinib for the Treatment of Alopecia Universalis
Topical Ruxolitinib may safely treat severe hair loss.
research Epidermal Growth Factor as a Biologic Switch in Hair Growth Cycle
EGF controls hair growth by regulating hair follicles' growth phases.
research Self-organization process in newborn skin organoid formation inspires strategy to restore hair regeneration of adult cells
Newborn mouse skin cells can grow hair and this process can be recreated in adult cells to potentially help with hair loss.
research Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
EGFR-targeting cancer drugs can cause skin rashes and other side effects.